ALK-Abello A/S Release: Three-Month Interim Report (Q1) 2014
5/8/2014 9:18:48 AM
Performance for the period (unaudited)
(Comparative figures for 2013 are shown in brackets / revenue growth is measured in local currencies)
Revenue and operating profit (EBITDA) in Q1 was strong. In particular, performance of allergy immunotherapy products in Europe exceeded expectations.
Help employers find you! Check out all the jobs and post your resume.